A cohort study showed that adults with T2DM prescribed a sodium-glucose cotransporter-2 (SGLT2) inhibitor had a lower rate of gout than those prescribed a glucagon-like peptide-1 (GLP1 agonist) (31). This evidence concerns the gene GCG and gout.